Skip to main content

Tourmaline Bio, Inc.

TRMLDelisted Oct 28, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001827506

Tourmaline Bio, Inc. was delisted on Oct 28, 2025; its insiders filed their last Form 4 on Oct 28, 2025; 134 institutions reported holding it in 13F filings for Q3 2025, worth $1.03B in total; no superinvestor held it.

Q3 2023 vs. Q2 2023

How the institutions holding Tourmaline Bio, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of TRML: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders5849−9
Shares26.2M27.4M+1.18M (+4.5%)
Value$79.7M$77.1M−$2.61M (−3.3%)

New holders (4)

Institutions that held Tourmaline Bio, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to TRML in Q3 2023
InstitutionSharesValue% of portfolio
Man Group plc–$141.5K0.00%
Freedom Wealth Alliance, LLC16,145$45.4K0.07%
Tower Research Capital LLC (TRC)962$2.70K0.00%
UBS Group AG139$3910.00%

Sold out (13)

Institutions that held Tourmaline Bio, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of TRML in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
HighTower Advisors, LLC448,359$1.36M
Scoggin Management LP289,608$880.4K
Jane Street Group, LLC91,391$277.8K
Corsair Capital Management, L.P.55,000$167.2K
Y-Intercept (Hong Kong) Ltd32,062$97.5K
Values First Advisors, Inc.32,009$97.3K
Occudo Quantitative Strategies LP28,902$87.9K
Prelude Capital Management, LLC15,727$47.8K
Two Sigma Securities, LLC14,649$44.5K
Commonwealth Equity Services, LLC13,000$40.0K
Acadian Asset Management LLC11,215$34.0K
Royal Bank of Canada3,440$10.0K
New York State Common Retirement Fund200$608